OLALA: An observational study of long-term responders to olaparib
Researchers in this study are trying to find out more about the mechanisms of action of a drug called olaparib. olaparib is a PARP inhibitor which is a targeted treatment for ovarian cancer. Researchers wish to find out why some women's ovarian cancer responds well to olaparib while other ovarian cancers don't. This information will help them to be…